

Indianapolis, Aug. 9, 2018

## Roche Diagnostics Earns 2019 Military Friendly Employer Designation

**Roche Diagnostics** (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has earned the 2019 [Military Friendly® Employer](#) designation. Institutions earning the Military Friendly® Employer designation were evaluated using both public data sources and responses from a proprietary survey. More than 200 companies participated in the Military Friendly® Employers portion of the 2019 Military Friendly® Companies survey.

Methodology, criteria and weightings were determined by VIQTORY with input from the Military Friendly® Advisory Council of independent leaders in the higher education and military recruitment community. Final ratings were determined by combining an organization's survey score with an assessment of the organization's ability to meet thresholds for Applicant, New Hire Retention, Employee Turnover, and Promotion & Advancement of veterans and military employees.

“We're thrilled to make this list for the second year in a row,” says Jay Graves, Vice President of Diabetes Care Sales and executive sponsor of the Indianapolis veterans business resource group. “We've found that people with military backgrounds are inherently good at connecting with a mission and are used to working through challenges and hardships. These skills are invaluable to our business.”

Roche will be showcased along with other 2019 Military Friendly® Employers in the December issue of G.I. Jobs® magazine, the January 2019 issue of Military Spouse Magazine, and on MilitaryFriendly.com.

###

### About Military Friendly® Employers

The Military Friendly® Employers list is created each year based on extensive research using public data sources for thousands of federal contractors nationwide, input of military employees, and responses to the proprietary, data driven Military Friendly® Employers survey from participating companies. The survey

questions, methodology, criteria and weightings were developed with the assistance of an independent research firm and an advisory council of educators and employers. Data calculations and tabulations were independently evaluated for completeness and accuracy by Ernst & Young. The survey is administered for free and is open to companies that have hired veterans in the past 12 months. Criteria for consideration can be found at [www.militaryfriendly.com](http://www.militaryfriendly.com).

### **About Roche**

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.

Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com).

For additional information or to arrange interviews, contact:

Roche Indy Contact:

Amberly Peterson, [amberly.peterson@roche.com](mailto:amberly.peterson@roche.com), 317-270-8064

VIQTORY:

Brian O'Malley Gordon C. James Public Relations [bomalley@gcjpr.com](mailto:bomalley@gcjpr.com) 4807038338